Advertisement

November 18, 2026

Procyrion Appoints Jason Whiting as CEO

KEY TAKEAWAYS

  • Procyrion appointed Jason Whiting as President and CEO, succeeding Eric S. Fain, MD, who is retiring after leading the company since 2018.
  • Dr. Fain will remain on the Board of Directors as Procyrion continues clinical development of its Aortix mechanical circulatory support device.
  • The Aortix system is under evaluation in the pivotal DRAIN-HF trial involving patients with acute decompensated heart failure and persistent congestion.

November 18, 2026—Procyrion, Inc. announced the appointment of Jason Whiting as President and Chief Executive Officer.

The company stated that Whiting succeeds Eric S. Fain, MD, who has served in the role since 2018. Dr. Fain has announced his plans to retire and will remain on Procyrion’s Board of Directors to support the company’s transition from clinical stage to commercial stage.

According to Procyrion, the company is developing the Aortix percutaneous mechanical circulatory support device to improve outcomes for patients with cardiac and renal impairment.

The company advised that the Aortix system is being evaluated in the DRAIN-HF pivotal trial, which is enrolling patients with acute decompensated heart failure who remain congested despite standard medical therapy (“cardiorenal syndrome”). The trial includes a registry arm for patients with end-stage heart failure whose persistent congestion and poor renal function place them at high risk to receive a left ventricular assist device or heart transplant.

As noted in the press release, Whiting most recently served as CEO of Avation Medical, a developer of a wearable neuromodulation therapy for overactive bladder. Previously, he was President of Zoll Cardiac Management Solutions for more than 8 years after serving as Vice President of Global Marketing and Clinical Operations.

“On behalf of the Board, I want to thank Eric for more than 8 years of exceptional leadership,” stated Gary Burbach, Chairman of the Board of Procyrion, in the press release. “Eric led the team to advance Aortix from prototype to a durable, robust design, which is now a Breakthrough-designated therapy in a pivotal trial. As DRAIN-HF progresses, the Board conducted a deliberate succession process to identify a leader with the commercial experience to guide Procyrion’s next phase. We are confident Jason is the right person to lead Procyrion’s team forward to complete our clinical trial activities, gain regulatory approval and prepare Aortix for market.”

Advertisement


November 16, 2026

TRIUMPH Pivotal Trial Begins for Laplace’s Transcatheter Tricuspid Valve Replacement System


)